Modernas

You might think a biotech company that created a new vaccine, using novel tech like mRNA-based therapeutics, in record time to help the world fight a historic pandemic like COVID-19 would still be flying high. That hasn’t been the case so far for Moderna, whose only FDA-approved product to date remains its COVID vaccine Spikevax and its various forms for teens and children. But a new analyst report from Oppenheimer released this week asserts the company’s pipeline of mRNA-based vaccine candidates, for infectious diseases…

Moderna said its research and development expenses soared in the fourth quarter. Photo: Simon Simard for The Wall Street Journal…

Biotechnology company Moderna has announced promising results from its massive Phase 3 trial testing an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. The data indicates the vaccine is nearly 84% effective at preventing moderate disease and the company expects to file for US Food and Drug Administration (FDA) approval this year.RSV infection can turn into a deadly respiratory disease for both the very young and very old. For over half a century researchers have been trying to develop an effective…

An experimental vaccine from Moderna Inc. significantly reduced the risk of a viral respiratory disease among older adults in a large clinical trial, the latest promising sign in drugmakers’ efforts to fight the deadly RSV virus.Based on the results, the Cambridge, Mass., company said Tuesday it would apply in the coming months for U.S. regulatory approval to sell its vaccine against RSV, which stands for respiratory syncytial virus. If regulators approve, it could become available by early…

A customized Moderna Inc. MRNA -6.89% vaccine combined with a Merck MRK 0.17% & Co. cancer drug helped ward off the recurrence of the skin cancer melanoma after surgery in patients in a mid-stage clinical trial, the companies said.The companies said Tuesday the combination of Moderna’s personalized cancer vaccine and Merck’s Keytruda cancer immunotherapy reduced patients’ risk of relapse or death by about 44%,…

…

The Centers for Disease Control and Prevention recommended use of Moderna Inc.’s Covid-19 vaccine in children ages 6 to 17 years.The CDC’s move on Friday means the youths, who have been able to get the Covid-19 vaccine made by Pfizer Inc. and its partner BioNTech SE, will also have the choice of Moderna’s shot. The Centers for Disease Control and Prevention recommended use of ModernaInc.’s Covid-19 vaccine in children ages 6 to 17 years.The CDC’s move on Friday means the youths, who have been able to get the Covid-19…

Advisers to the Centers for Disease Control and Prevention are set to decide whether to recommend Moderna Inc.’s Covid-19 vaccine for children ages 6 to 17 years. Children in the age group already have access to Covid-19 vaccines made by Pfizer Inc. and its partner BioNTech SE. The advisers are scheduled to discuss on Thursday whether Moderna’s shot should also be made available for that age range.…

Moderna Inc. said a modified version of its Covid-19 vaccine induced potent immune responses against fast-spreading Omicron subvariants among volunteers in a new study. One month after receiving the company’s tweaked shot, study subjects’ neutralizing antibodies against Omicron subvariants BA.4 and BA.5 increased significantly, regardless of whether they were previously infected, Moderna said Wednesday. The company said the new data reinforce…

A panel of advisers to the Food and Drug Administration is set to meet Tuesday to consider whether use of Moderna Inc.’s Covid-19 vaccine should be expanded to include children ages 6 through 17.The advisory committee is expected to vote Tuesday afternoon on whether the benefits of vaccinating children in this age group outweigh the risks. The FDA will consider the vote in making a final decision on whether to clear the vaccine for use in children 6 years and older. An FDA authorization could…